集采注射用头孢他啶治疗肺部感染的有效性安全性和经济性评价  

Evaluation of the Efficacy,Safety and Economy of Centrally Procured Ceftazidime Injection on Treating Pulmonary Infections

作　　者：李晓东 姜坤 彭芳 崔朴梅 LI Xiaodong;JIANG Kun;PENG Fang;CUI Pumei(Department of Pharmacy,the First People's Hospital of Anning City,Anning 650300,China)

机构地区：[1]安宁市第一人民医院药学部,云南安宁650300

出　　处：《医药导报》2024年第12期2038-2041,共4页Herald of Medicine

基　　金：昆明市卫生健康委卫生科研课题项目(2022-13-01-009)。

摘　　要：目的评价集采注射用头孢他啶治疗肺部感染的有效性、安全性和经济性,为临床治疗决策提供参考。方法基于中国医院药物警戒系统(CHPS)主动监测和药品评价功能,采用回顾性分析方法,采集安宁市第一人民医院2021年2月—2022年8月使用注射用头孢他啶治疗肺部感染的203例患者的电子诊疗数据,根据使用药物的不同分为2组:集采注射用头孢他啶组(102例)和非集采注射用头孢他啶组(101例),以有效率评价有效性,不良反应发生率评价安全性,成本-效果分析评价经济性。结果治疗有效率:集采组90.20%,非集采组91.09%,差异无统计学意义(P>0.05);不良反应发生率:集采组10.78%,非集采组5.94%,差异无统计学意义(P>0.05);平均成本-效果比(C/E):集采组1.56±0.86,非集采组18.96±9.38,集采组C/E值更小,敏感度分析结果与成本效果分析结果一致。结论集采注射用头孢他啶与非集采注射用头孢他啶具有相同的疗效和安全性,经济性更优,临床使用头孢他啶治疗肺部感染时,可优先选用集采品种。Objective To evaluate the efficacy,safety and economy of centrally procured ceftazidime injection for treating pulmonary infections,and to provide a reference for clinical therapeutic decisions.Methods Based on the active monitoring and drug evaluation functions of the China Hospital Pharmacovigilance System(CHPS),a retrospective analysis was conducted.Electronic medical records of 203 patients treated with ceftazidime injection for pulmonary injections in our hospital from February 2021 to August 2022 were collected.Patients were divided into two groups based on the type of ceftazidime used,the centrally procured ceftazidime group(102 cases)and the non-centrally procured ceftazidime group(101 cases).Efficacy was evaluated by the effectiveness rate,safety by the incidence of adverse reactions,and economy by cost-effectiveness analysis.Differences between the two groups were compared.Results Treatment efficiency was 90.20%in the centrally procured group and 91.09%in the non-centrally procured group,with no statistically significant difference(P>0.05).The incidence of adverse reactions was 10.78%in the centrally procured group and 5.94%in the non-centrally procured group,with no statistically significant difference(P>0.05).The average cost-effectiveness ratio(C/E)was 1.56±0.86 in the centrally procured group and 18.96±9.38 in the non-centrally procured group,indicating a smaller C/E value for the centrally procured group.Sensitivity analysis results were consistent with the cost-effectiveness analysis results.Conclusion Centrally procured ceftazidime injection has equivalent efficacy and safety compared to non-centrally procured ceftazidime,with improved economic value.Therefore,the centrally procured variant should be given priority when using ceftazidime for the treatment of pulmonary infections.

关 键 词：注射用头孢他啶 肺部感染 集中采购 有效性 安全性 经济性 

分 类 号：R978.1[医药卫生—药品] R563[医药卫生—药学]